TNXP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Tonix Pharmaceuticals Holding Corp (TNXP) is not a strong buy at this moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The technical indicators are bearish, the options data suggests low trading sentiment, and the company’s financial performance shows improvement in revenue and gross margin but significant losses in net income and EPS. Without positive news or strong catalysts, it is better to hold off on investing in this stock for now.
The technical indicators for TNXP are bearish. The MACD histogram is negative and expanding, RSI is neutral at 28.861, and moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 15.184), and the pivot point is at 16.581, indicating limited upward momentum.
Revenue increased by 16.58% YoY in Q3 2025, and gross margin improved by 30.18% to 58.45%.
Net income remains significantly negative at -$32,010,000, despite a 125.22% YoY improvement. EPS dropped drastically by -84.31% YoY. No recent news, analyst upgrades, or significant trading trends from hedge funds or insiders. Congress trading data is also absent.
In Q3 2025, revenue increased to $3,290,000 (up 16.58% YoY), gross margin improved to 58.45% (up 30.18% YoY), but net income remains negative at -$32,010,000 (though improved by 125.22% YoY). EPS dropped significantly to -3.59 (-84.31% YoY).
No recent analyst ratings or price target changes are available.
